Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186450 | 0.84 | HSPA5 (0.46) | CALM1HTR2AL3MBTL1TSHRCYP3A4 | |
| SCHEMBL5000663 | 0.82 | POLB (0.44) | TSHRCYP3A4CYP2D6CYP2C19HPGD | |
| SCHEMBL972711 | 0.81 | CALM1 (0.69) | CALM1HTR2ABCL2BCL2L1L3MBTL1 | |
| SCHEMBL5535889 | 0.78 | HTR1A (0.48) | HTR2ANR1H2HPGDSMN1; SMN2 | |
| SCHEMBL5004420 | 0.78 | LTA4H (0.60) | L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL6548117 | 0.75 | HTR2A (0.56) | CALM1HTR2ABCL2BCL2L1L3MBTL1 | |
| SCHEMBL22675719 | 0.75 | CALM1 (0.52) | CALM1HTR2ABCL2BCL2L1L3MBTL1 | |
| SCHEMBL17007958 | 0.75 | HTR2A (0.56) | CALM1HTR2ABCL2BCL2L1L3MBTL1 | |
| SCHEMBL5536486 | 0.75 | BID (0.50) | BCL2L1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5541173 | 0.75 | HTR2A (0.48) | HTR2ABCL2L1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047707-A | Direct cross coupling method of sulfoxide ylide and aryl fluorosulfonate | 南京工业大学 | 2024-05-17 | — | — | CN | claimed |
| US-20170216248-A1 | Enhanced Erythropoiesis and Iron Metabolism | FIBROGEN, INC. | 2017-08-03 | — | — | US | claimed |
| EP-2325639-B1 | CYSTATIN C ADSORPTION INHIBITOR | DENKA SEIKEN KK (JP) | 2016-03-30 | — | — | EP | claimed |
| CN-104877981-A | Acid proteinase culture medium | HUANG HONGLIN | 2015-09-02 | — | — | CN | claimed |
| CN-102187221-B | Cysteine proteinase inhibitor C adsorption inhibitor | DENKA SEIKEN CO.,LTD. (JP) | 2015-08-12 | — | — | CN | claimed |
| US-9096525-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION, LLC (US) | 2015-08-04 | — | — | US | claimed |
| CN-102187221-A | Cystatin c adsorption inhibitor | DENKA SEIKEN KK | 2011-09-14 | — | — | CN | claimed |
| US-20110143457-A1 | CYSTATIN C ADSORPTION INHIBITOR | DENKA COMPANY LIMITED (JP) | 2011-06-16 | — | — | US | claimed |
| EP-2325639-A1 | CYSTATIN C ADSORPTION INHIBITOR | DENKA SEIKEN CO., LTD. (JP) | 2011-05-25 | — | — | EP | claimed |
| EP-1470138-B1 | MMP INHIBITORS | LEO PHARMA AS (DK) | 2006-01-18 | — | — | EP | claimed |
| US-6521606-B2 | 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2003-02-18 | — | — | US | claimed |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-08-01 | — | — | US | claimed |
| WO-2002006293-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA A/S (DK) | 2002-01-24 | — | — | WO | claimed |
| CN-1310200-A | Lustrous fireproof butanediol terephthalate | GUANGZHOU JINFA S & T DEV CO L (CN) | 2001-08-29 | — | — | CN | claimed |
| EP-0295916-B1 | Sizing agents for carbon fibers | TAKEMOTO OIL & FAT CO LTD (JP) | 1993-12-22 | — | — | EP | claimed |
| US-4874782-A | PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1989-10-17 | — | — | US | claimed |
| EP-0209274-A2 | Furanone derivatives | ELI LILLY AND COMPANY (US) | 1987-01-21 | — | — | EP | claimed |
| EP-0012722-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3-SUBSTITUTED 2-(2',2'-DIHALOVINYL)-CYCLOPROPANE-1-CARBOXYLIC ACIDS AND THEIR DERIVATIVES; 4-(2',2',2'-TRIHALOETHYL)-CYCLOBUTANE-1-SULPHONIC ACID SALTS AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1981-12-09 | — | — | EP | claimed |
| EP-0012722-A1 | Process for the preparation of optically active 3-substituted 2-(2',2'-dihalovinyl)-cyclopropane-1-carboxylic acids and their derivatives; 4-(2',2',2'-trihaloethyl)-cyclobutane-1-sulphonic acid salts and their preparation | CIBA-GEIGY AG (CH) | 1980-06-25 | — | — | EP | claimed |
| US-3948877-A | POLYACRYLONITRILE, ACID MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216248-A1 | Enhanced Erythropoiesis and Iron Metabolism | EPOR, TFRC, HAMP | CALM1 2883/4885HTR2A 4384/4885BCL2 1468/4885 |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | MMP1, MMP9, MMP8 | CALM1 3547/4885HTR2A 3588/4885BCL2 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.